MedTrace Logo

PTH & Ibandronate Combination Study (PICS)

NCT00683163 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2013-11-05

Study results available
· View outcomes & findings →

Summary

This study will test in several innovative ways, several different combinations of PTH and oral monthly ibandronate for the treatment of osteoporosis in postmenopausal women. The intension is to provide other options for treatment than the current standard 2 year course of drug therapy. These options may lead to treatment where the two years of therapy are spread over several years.

Conditions

Interventions

DRUG

PTH(1-84)

1.4 mg injected subcutaneously (in the abdomen) daily

DRUG

Ibandronate

150mg by mouth once monthly

OTHER

Placebo injection

Daily injections as placebo for PTS 1-84

OTHER

Placebo pills

Monthly pills as placebo for oral ibandronate

Sponsors & Collaborators

Principal Investigators

  • Dennis M. Black, PhD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683163 on ClinicalTrials.gov